Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis.
Yingli HeS J YangChuanhua HuJ DongH GaoT T YanJingFeng LiuYuan YanagD F RenL ZhuY R ZhaoT Y ChenPublished in: Alimentary pharmacology & therapeutics (2017)
A half dose of sofosbuvir (200 mg once daily) plus a full dose of daclatasvir (60 mg once daily) were suitable for the treatment of acute HCV-infected patients who were undergoing end-stage renal disease and were on haemodialysis.